New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience’s Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical… Read More
Canary Quantiles™ Recovery Curves Compare Observed Gait Performance versus Population Gait Performance During a Patient’s Recovery from Total Knee Replacement Surgery Quantiles™ Recovery Curves Utilize Data Derived from Persona IQ® to Help Healthcare Professionals… Read More
Company remains on track for Phase 2 data readout in Q2 2023 VICTORIA, BC — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an… Read More
Jardiance® (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged 10-17 living with… Read More
A $33.8 million gift has been donated to the UBC Faculty of Medicine and VGH & UBC Hospital Foundation for multiple sclerosis (MS) research and care — the largest known… Read More
